Загрузка...

Update on recent preclinical and clinical studies of T790M mutant-specific irreversible epidermal growth factor receptor tyrosine kinase inhibitors

The first- and second-generation epidermal growth factor receptor tyrosine kinase inhibitors (1/2G EGFR-TKIs) gefitinib, erlotinib, and afatinib have all been approved as standard first-line treatments for advanced EGFR mutation-positive non-small cell lung cancer. The third-generation (3G) EGFR-TKI...

Полное описание

Сохранить в:
Библиографические подробности
Опубликовано в: :J Biomed Sci
Главные авторы: Liao, Bin-Chi, Lin, Chia-Chi, Lee, Jih-Hsiang, Yang, James Chih-Hsin
Формат: Artigo
Язык:Inglês
Опубликовано: BioMed Central 2016
Предметы:
Online-ссылка:https://ncbi.nlm.nih.gov/pmc/articles/PMC5135794/
https://ncbi.nlm.nih.gov/pubmed/27912760
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s12929-016-0305-9
Метки: Добавить метку
Нет меток, Требуется 1-ая метка записи!